Geron Corporation (GERN)
- Previous Close
1.2100 - Open
1.2000 - Bid 1.2700 x 100
- Ask 1.3100 x 3900
- Day's Range
1.1900 - 1.2800 - 52 Week Range
1.1700 - 5.3400 - Volume
13,761,863 - Avg. Volume
15,085,080 - Market Cap (intraday)
808.886M - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2100 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.69
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
www.geron.comRecent News: GERN
View More
Performance Overview: GERN
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GERN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GERN
View MoreValuation Measures
Market Cap
808.89M
Enterprise Value
533.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.23
Price/Book (mrq)
3.02
Enterprise Value/Revenue
4.59
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-119.54%
Return on Assets (ttm)
-16.07%
Return on Equity (ttm)
-45.35%
Revenue (ttm)
116.29M
Net Income Avi to Common (ttm)
-139.02M
Diluted EPS (ttm)
-0.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
396.88M
Total Debt/Equity (mrq)
45.40%
Levered Free Cash Flow (ttm)
-142.38M